{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:30:39Z","timestamp":1793205039661,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["JP25K19187"],"award-info":[{"award-number":["JP25K19187"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The uptake of hypofractionated radiotherapy in Japan is not well documented. This study examined trends in the proportion of patients with breast or prostate cancer who received hypofractionated radiotherapy, using hospital-based cancer registry data linked to Diagnostic Procedure Combination records from 69 institutions in Osaka Prefecture (diagnosis years: 2019\u201323). Eligible patients included 6475 women with unilateral breast cancer (pTisN0M0, pT1\u20132N0M0 or cT1\u20132N0M0 before neoadjuvant therapy) who underwent partial mastectomy and radiotherapy at the same hospital and 3274 men with cT1\u20133N0M0 prostate cancer treated with external-beam radiotherapy without surgery or brachytherapy. The use of hypofractionated radiotherapy was determined through insurance claims. Among the patients with breast cancer, the proportion of those who received hypofractionated radiotherapy increased from 41% in 2019 to 81% in 2023. In 2023, this proportion was highest at facilities with high radiotherapy volume (95%), followed by those with medium (84%) and low (67%) volumes. Among the patients with prostate cancer, the proportion of those who received hypofractionated radiotherapy (hypofractionated intensity-modulated radiotherapy or stereotactic body radiotherapy) increased from 25% in 2019 to 48% in 2023, although the increase slowed after 2021. In 2023, hypofractionated radiotherapy use reached 79% at high-volume facilities, while proportions were lower at medium- (30%) and low-volume (17%) facilities. Hypofractionated radiotherapy use has increased in patients with breast and prostate cancers. However, its adoption in prostate cancer treatment remains limited, particularly in medium- and low-volume facilities. These findings suggest that certain barriers limit its implementation and highlight the need to address them.<\/jats:p>","DOI":"10.1093\/jrr\/rraf082","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:06:29Z","timestamp":1763039189000},"page":"104-113","source":"Crossref","is-referenced-by-count":3,"title":["Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-0227","authenticated-orcid":false,"given":"Toshiki","family":"Ikawa","sequence":"first","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]},{"name":"Department of Radiation Oncology, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-3287","authenticated-orcid":false,"given":"Toshitaka","family":"Morishima","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-8637","authenticated-orcid":false,"given":"Kayo","family":"Nakata","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-2970","authenticated-orcid":false,"given":"Yoshihiro","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-8498","authenticated-orcid":false,"given":"Kenji","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-2213","authenticated-orcid":false,"given":"Naoyuki","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-4971","authenticated-orcid":false,"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026013002565835400_ref1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12282-024-01568-4","article-title":"The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition","volume":"31","author":"Yoshimura","year":"2024","journal-title":"Breast Cancer"},{"key":"2026013002565835400_ref2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"2026013002565835400_ref3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026013002565835400_ref4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/jjco\/hyab024","article-title":"Final analysis of a multicenter single-arm confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906","volume":"51","author":"Nozaki","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2026013002565835400_ref5","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026013002565835400_ref6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"2026013002565835400_ref7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijrobp.2020.09.004","article-title":"Trends in use of hypofractionated whole breast radiation in breast cancer: an analysis of the National Cancer Database","volume":"109","author":"Woodward","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026013002565835400_ref8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","article-title":"Increasing use of shorter-course radiotherapy for prostate cancer","volume":"9","author":"Yu","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026013002565835400_ref9","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.prro.2024.04.010","article-title":"Increase in hypofractionated radiation therapy among patients with invasive breast cancer or ductal carcinoma in situ: who is left behind?","volume":"14","author":"Booth","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026013002565835400_ref10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(20)30743-9","article-title":"The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study","volume":"22","author":"Spencer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026013002565835400_ref11","doi-asserted-by":"publisher","first-page":"21032","DOI":"10.1002\/cam4.6661","article-title":"The impact of the COVID-19 pandemic on radiotherapy delivery in Japan: an observational study based on the national database","volume":"12","author":"Tamari","year":"2023","journal-title":"Cancer Med"},{"key":"2026013002565835400_ref12","doi-asserted-by":"publisher","first-page":"101291","DOI":"10.1016\/j.adro.2023.101291","article-title":"Challenges and opportunities with the use of hypofractionated radiation therapy in cancer care: regional perspectives from South Korea, Japan, Singapore, and Australia","volume":"8","author":"Akimoto","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2026013002565835400_ref13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0167-8140(00)00214-0","article-title":"Palliative radiotherapy practice within western European countries: impact of the radiotherapy financing system?","volume":"56","author":"Lievens","year":"2000","journal-title":"Radiother Oncol"},{"key":"2026013002565835400_ref14","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1200\/JOP.2015.007385","article-title":"Radiation oncology practice: adjusting to a new reimbursement model","volume":"12","author":"Konski","year":"2016","journal-title":"J Oncol Pract"},{"key":"2026013002565835400_ref15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","article-title":"Japanese universal health coverage: evolution, achievements, and challenges","volume":"378","author":"Ikegami","year":"2011","journal-title":"Lancet"},{"key":"2026013002565835400_ref16","doi-asserted-by":"publisher","first-page":"101555","DOI":"10.1016\/j.adro.2024.101555","article-title":"Impact of the COVID-19 pandemic on hypofractionated radiation therapy use for breast cancer in Japan: a nationwide study","volume":"9","author":"Fujita","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"2026013002565835400_ref17","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/cas.14847","article-title":"Three-year survival from diagnosis in surgically treated patients in designated and nondesignated cancer care hospitals in Japan","volume":"112","author":"Okawa","year":"2021","journal-title":"Cancer Sci"},{"key":"2026013002565835400_ref18","volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program. Rare Cancer Classification","author":"National Cancer Institute"},{"key":"2026013002565835400_ref19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2026013002565835400_ref20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026013002565835400_ref21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ijrobp.2014.06.038","article-title":"Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: a national cancer data base analysis","volume":"90","author":"Wang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026013002565835400_ref22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.radonc.2020.10.008","article-title":"Hypofractionated radiation therapy for breast cancer: preferences amongst radiation oncologists in Europe \u2013 results from an international survey","volume":"155","author":"Ratosa","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026013002565835400_ref23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","article-title":"Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey","volume":"157","author":"Rodin","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026013002565835400_ref24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026013002565835400_ref25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijrobp.2010.04.042","article-title":"Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"81","author":"Smith","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026013002565835400_ref26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ijrobp.2020.08.038","article-title":"Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity","volume":"109","author":"Lalani","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026013002565835400_ref27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijrobp.2021.10.012","article-title":"Disease control after hypofractionation versus conventional fractionation for triple negative breast cancer: comparative effectiveness in a large observational cohort","volume":"112","author":"Jagsi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026013002565835400_ref28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdu090","article-title":"Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy","volume":"25","author":"Bane","year":"2014","journal-title":"Ann Oncol"},{"key":"2026013002565835400_ref29","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026013002565835400_ref30","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026013002565835400_ref31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","article-title":"Japanese clinical practice guidelines for prostate cancer 2023","volume":"31","author":"Kohjimoto","year":"2024","journal-title":"Int J Urol"},{"key":"2026013002565835400_ref32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/jrr\/rrae056","article-title":"Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer","volume":"65","author":"Serizawa","year":"2024","journal-title":"J Radiat Res"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/1\/104\/66398662\/rraf082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/1\/104\/66398662\/rraf082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:57:04Z","timestamp":1769759824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/67\/1\/104\/8424672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,1,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraf082","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}